Aurobindo Pharma (Aurobindo Pharma) 3-Year EPS without NRI Growth Rate : 4.10% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Aurobindo Pharma 3-Year EPS without NRI Growth Rate?

Aurobindo Pharma's EPS without NRI for the three months ended in Mar. 2024 was $0.00.

During the past 12 months, Aurobindo Pharma's average EPS without NRI Growth Rate was 71.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 4.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Aurobindo Pharma was 280.90% per year. The lowest was -13.90% per year. And the median was 11.95% per year.

Competitive Comparison of Aurobindo Pharma's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurobindo Pharma's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's 3-Year EPS without NRI Growth Rate falls into.

Aurobindo Pharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Aurobindo Pharma (GREY:ARBQY) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Aurobindo Pharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurobindo Pharma (Aurobindo Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (GREY:ARBQY) » Definitions » 3-Year EPS without NRI Growth Rate

Traded in Other Exchanges

AUROPHARMA:India 524804:India

Address

Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032

Website

https://www.aurobindo.com

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (Aurobindo Pharma) Headlines

From GuruFocus

Aurobindo Pharma Wins Company of the Year and Acquisition of the Year Awards at the Global Generics & Biosimilars Awards 2019

By PRNewswire PRNewswire • 11-21-2019